Sarcoma of the Year: Small Round Blue Cell Tumor

(P 424) INTERNAL TANDEM DUPLICATION OF BCOR (BCOR-ITD) ALTERS THE TUMOR EPIGENOME

(P 425) CHARACTERIZATION OF RHABDOMYOSARCOMA WITH PAX7::FOXO1 FUSIONS: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP

(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES

(P 427) UNDERSTANDING THE MOLECULAR DRIVERS THAT REGULATE EWING SARCOMA CELL FATE

(P 428) COMPREHENSIVE GENOMIC PROFILING OF CIC-DUX4 SARCOMA (CDS) CELL LINES AND MODELS

(P 429) SARCOMA FUSION GENE ANALYSIS YIELDS PROMISING HLA ANTIGEN FIT IN EWING SARCOMA AND DESMOPLASTIC SMALL ROUND CELL TUMOR

(P 430) UNIQUE HISTOLOGIC MORPHOLOGY OF EWING SARCOMA CELLS THAT HARBOR TP53 MUTATIONS

(P 431) TREATMENT STRATEGY AND PROGNOSTIC FACTORS IN EXTRASKELETAL EWING SARCOMA: AN INSTITUTIONAL RETROSPECTIVE ANALYSIS

(P 432) LONG-LASTING DISEASE CONTROL WITH TRABECTEDIN IN A CASE OF METASTATIC EWSR1::PATZ1 SARCOMA

(P 433) A 20-YEAR MONOCENTER EXPERIENCE ON CLINICAL CHARACTERISTICS AND OUTCOME OF EXTRASKELETAL EWING SARCOMA.

(P 434) MECHANISMS OF CHEMORESISTANCE IN CIC-DUX4 SARCOMA AS DETERMINED BY IN VIVO FUNCTIONAL GENOMICS

(P 435) ONCOGENIC FUSION YWHAE::NUTM2 DISRUPT EP300/BCOR INTERACTION

(P 436) OUTCOME PROGNOSTICATORS IN ADOLESCENTS AND ADULTS WITH BONE SARCOMAS IN LOW-MIDDLE-INCOME COUNTRIES

(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT

(P 438) ALVEOLAR RHABDOMYOSARCOMA WITH "BURKITT-LIKE" MORPHOLOGY IS ASSOCIATED WITH HIGH AMPLIFICATION OF MYCL

(P 440) LONG TERM OUTCOMES OF EWING SARCOMA OF THE FOOT AND ANKLE

(P 441) LONG VERSUS SHORTER SCHEDULES OF VINCRISTINE, IRINOTECAN AND TEMOZOLOMIDE (VIT) FOR RELAPSED OR REFRACTORY EWING SRACOMA: A RANDOMISED CONTROLLED PHASE 2 TRIAL

(P 442) LONG-TERM OUTCOME AND RELAPSE PATTERNS IN EWING SARCOMA PATIENTS WITH EXTENSIVE LUNG/PLEURAL METASTASES AFTER A COMPLETE RESPONSE TO SYSYEMIC THERAPY

(P 443) SURGICAL RESECTION OF EXTREMITY EWING'S SARCOMA BASED ON POST-CHEMOTHERAPY TUMOUR VOLUME RESULTS IN SAFE MARGINS

(P 444) TWO CASES OF BRAIN METASTASES OF CD99 POSITIVE SMALL ROUND BLUE CELL TUMORS

(P 445) ISOTOXIC RADIOTHERAPY DOSE ESCALATION IN UNRESECTABLE PEDIATRIC EWING SARCOMA: A DOSIMETRIC FEASIBILITY STUDY

(P 446) SYNERGISTIC TARGETING OF KIF11 AND AURKA TO IMPROVE OUTCOMES FOR EWING SARCOMA

(P 447) TARGETING FOCAL ADHESION KINASE AUGMENTS THE THERAPEUTIC POTENTIAL OF BROMODOMAIN INHIBITORS IN EWING SARCOMA

(P 448) CAF-LIKE EWING SARCOMA CELLS DEPOSIT PRO-TUMORIGENIC EXTRACELLULAR MATRIX IN RESPONSE TO TGF-BETA SIGNALING

(P 449) CIC-DUX4 sarcomas: A single-center review of clinical features and molecular aberrations identified through DNA sequencing

(P 450) INVESTIGATING THE THERAPEUTIC POTENTIAL OF SMALL MOLECULE INHIBITOR INOBRODIB AS A TREATMENT ALTERNATIVE FOR CIC-DUX4 SARCOMA

(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL

(P 452) SECONDARY GENOMIC LANDSCAPE OF CIC::DUX4 FUSION SARCOMAS

(P 453) ROLE OF SECOND-LINE TREATMENT IN EWING SARCOMAS WITH POOR PROGNOSIS AT DIAGNOSIS: EXPERIENCE OF A SPANISH REFERENCE CENTER.

(P 454) TREATMENT PATTERNS AND OUTCOMES IN PEDIATRIC AND ADULT PATIENTS WITH EWING AND UNDIFFERENTIATED ROUND BLUE CELL SARCOMAS IN ALBERTA

(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP

(P 456) SECLIDEMSTAT TREATMENT BLOCKS THE TRANSCRIPTIONAL FUNCTION OF MULTIPLE FET-FUSION PROTEINS